Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Figure 1

Patient disposition. *ReAct was followed by ReAlise when ADA was commercially licensed, giving patients the opportunity to be further observed for safety and effectiveness over 5 years or more. †Discontinuations and completions are listed for the entire duration of the ReAlise study. ADA, adalimumab; ReAct, the Research in Active Rheumatoid Arthritis phase 3b study; ReAlise, the Registry of HUMIRA™ in RA: a Long-Term Investigation of Safety and Efficacy observational follow-up study.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us